Ask AI

Capsule Summaries

Share

Program Content

Activities

  • ISLEND 1 Switch to ISL LEN
    ISLEND-1: Switch From BIC/FTC/TAF to Once-Weekly ISL/LEN in People With Virologically Suppressed HIV
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: July 29, 2026

  • ISLEND 2 Switch to ISL LEN
    ISLEND-2: Switch From Standard-of-Care to Once-Weekly ISL/LEN in People With Virologically Suppressed HIV
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: July 30, 2026

  • Efficacy of DOR ISL With Baseline RAMs
    Efficacy of Switch to DOR/ISL With Baseline RAMs: Retrospective Analysis of 3 Phase III Trials
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: July 31, 2026

  • Phase IIb MK 8591B 060
    Phase IIb MK-8591B-060: Switch to Once-Weekly Islatravir + Ulonivirine in Adults With Virologically Suppressed HIV
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: July 31, 2026

  • PURPOSE 1 OLE
    PURPOSE 1 OLE: Twice-Yearly LEN PrEP in Adolescent Cisgender Women
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: July 31, 2026

  • BICSTaR Switch to BIC FTC TAF
    BICSTaR: Real-world Switch to BIC/FTC/TAF in Treatment-Experienced People Living With HIV and Detectable HIV-1 RNA
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: July 31, 2026

  • Twice Yearly LEN TAB ZAB
    Phase II Study of Twice-Yearly LEN + TAB + ZAB in People Living With Virologically Suppressed HIV: Wk 104 Results
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: July 31, 2026

  • PrIMO
    PrIMO: Prospective Cohort Study Evaluating the Safety of LA CAB vs Oral PrEP During Pregnancy in Malawi
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: July 31, 2026

  • VOGUE
    VOGUE: DTG/3TC vs BIC/FTC/TAF as Initial ART for People Living With HIV
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: August 03, 2026

  • LATA Adolescent LA CAB RPV
    LATA: Switch to LA CAB + RPV vs DTG/3TC/TDF in Adolescents Living With HIV 
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: August 03, 2026

  • PURPOSE 2 OLE
    PURPOSE 2 OLE: Twice-Yearly LEN PrEP in Men and Gender-Diverse Individuals
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: August 03, 2026

  • LA CAB PrEP Discordant HIV Test
    ImPrEP CAB Brasil: Early Detection of HIV With LA CAB PrEP 
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: August 04, 2026

  • MK 8591A 053
    MK-8591A-053: Subgroup Analysis of DOR/ISL vs BIC/FTC/TAF in Treatment-Naive People Living With HIV
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: August 04, 2026

  • LA CAB PrEP in Women
    Real-world Experience With LA CAB PrEP in Women: US OPERA Cohort 
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: August 04, 2026

  • MK 8591A 051 Post Hoc Analysis
    MK-8591A-051 Post Hoc Analysis: Switch From Complex ART to DOR/ISL in People Living With Virologically Suppressed HIV
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: August 05, 2026

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC dba Decera Clinical Education

Supporters

This activity is supported through independent educational grants from Gilead Sciences, Inc., Merck & Co., Inc., Rahway, NJ, USA, and ViiV Healthcare.

Gilead Sciences, Inc.

Merck & Co., Inc., Rahway, NJ, USA

ViiV Healthcare

Partners

International AIDS Society

ProCE Banner